Table 3.

Parameters of thromboxane B2 and prostaglandin E2 and indicator of COX-1-/COX-2-activity in the subjects classified by CYP2C9 genotype.

			TxB2			PgE2
CYP2C9 genotype	Code	Baselineconcentration(µg L−1)	AUC0−10(µg/L h)	period of 50%inhibitio(h)	Baselineconcentration(µg L−1)	AUC0−10(µg/L h)	period of conc. < 10 µg L−1(h)
*1/*1	1	175	1164	3.5	92	378	1.7
	16	140	1386	1.5	61	269	3.7
	25	50	385	3.8	21	81	6.2
	Mean	122	978	2.9	58	242	3.9
*1/*2	2	130	1111	1.8	55	338	3.4
	22	75	544	2.5	18	35	9.2
	23	70	1325	1.7	247	303	3.5
	24	100	1672	1.3	200	490	2.4
	Mean	94	1163	1.8	130	292	4.6
*1/*3	7	110	578	1.9	76	443	5.2
	11	75	516	2.9	33	215	3.3
	12	105	639	3.2	30	220	3.9
	20	50	740	1.8	23	78	4.7
	Mean	85	618	2.5	41	239	4.3
*2/*2	3	30	240	1.4	54	238	2.4
	18	120	1257	2.3	249	460	3.0
	33	145	2488	1.5	107	258	4.7
	Mean	98	1329	1.7	137	318	3.4
*2/*3	4	120	1479	2.3	47	90	5.5
	9	100	479	3.0	114	876	1.4
	19	120	1172	3.7	14	51	10.2
	Mean	113	1043	3.0	59	339	5.7
*3/*3	5	45	430	1.6	102	346	3.7
	13	80	826	2.5	63	201	3.4
	14	150	1535	2.0	102	319	4.3
	Mean	92	930	2.0	89	288	3.8
All	Mean(95%CI)	100(81–118)	949(701–1196)	2.3(1.9–2.7)	85(52–119)	284(193–376)	4.3(3.3–5.3)

Baseline: drawn from values before decline; AUC 0–10: Area under the concentration-time course during the first 10 h after medication; TxB2 period of 50% inhibition: period of time with TxB2 values under 50% of baseline; PgE2 period of conc. < 10 µg L⁻¹: period of time with PgE2-concentrations smaller than 10 µg L⁻¹.